Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

The outcomes of patients with multiple myeloma (MM) refractory to immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) remain poor. In this study, we performed whole genome and transcriptome sequencing of 39 heavily pretreated relapsed/refractory MM (RRMM) patients to identify mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Giesen, Nicola, Paramasivam, Nagarajan, Toprak, Umut H., Huebschmann, Daniel, Xu, Jing, Uhrig, Sebastian, Samur, Mehmet, Bähr, Stella, Fröhlich, Martina, Mughal, Sadaf S., Mai, Elias K., Jauch, Anna, Müller-Tidow, Carsten, Brors, Benedikt, Munshi, Nikhil, Goldschmidt, Hartmut, Weinhold, Niels, Schlesner, Matthias, Raab, Marc S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335090/
https://www.ncbi.nlm.nih.gov/pubmed/35045690
http://dx.doi.org/10.3324/haematol.2021.279360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335090/
https://www.ncbi.nlm.nih.gov/pubmed/35045690
http://dx.doi.org/10.3324/haematol.2021.279360

Ejemplares similares